4-hydroxy-5,6-dihydropyrones .2. Potent non-peptide inhibitors of HIV protease

被引:60
|
作者
Tait, BD
Hagen, S
Domagala, J
Ellsworth, EL
Gajda, C
Hamilton, HW
Prasad, JVNV
Ferguson, D
Graham, N
Hupe, D
Nouhan, C
Tummino, PJ
Humblet, C
Lunney, EA
Pavlovsky, A
Rubin, J
Gracheck, SJ
Baldwin, ET
Bhat, TN
Erickson, JW
Gulnik, SV
Liu, BS
机构
[1] WARNER LAMBERT PARKE DAVIS, PARKE DAVIS PHARMACEUT RES DIV, DEPT BIOCHEM, ANN ARBOR, MI 48105 USA
[2] WARNER LAMBERT PARKE DAVIS, PARKE DAVIS PHARMACEUT RES DIV, DEPT BIOMOL STRUCT & DRUG DESIGN, ANN ARBOR, MI 48105 USA
[3] NCI, FREDERICK CANC RES & DEV CTR,DYNCORP,PRI, STRUCT BIOCHEM PROGRAM, FREDERICK, MD 21702 USA
关键词
D O I
10.1021/jm970615f
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The 4-hydroxy-5,6-dihydropyrone template was utilized as a flexible scaffolding from which to build potent active site inhibitors of HIV protease. Dihydropyrone Ic (5,6-dihydro-4-hydroxy-6-phenyl-3-[(2-phenylethyl)thio]-2H-pyran-2-one) was modeled in the active site of HIV protease utilizing a similar binding mode found for the previously reported 4-hydroxybenzopyran-2-ones. Our model led us to pursue the synthesis of 6,6-disubstituted dihydropyrones with the aim of filling S-1 and S-2 and thereby increasing the potency of the parent dihydropyrone Ic which did not fill S-2. Toward this end we attached various hydrophobic and hydrophilic side chains at the 6-position of the dihydropyrone to mimic the natural and unnatural amino acids known to be effective substrates at P-2 and P-2'. Parent dihydropyrone Ic (IC50 = 2100 nM) was elaborated into compounds with greater than a 100-fold increase in potency [18c, IC50 = 5 nM, 5-(3,6-dihydroxy-6-hydroxy-6-oxo-2-phenyl-5-[2-phenylethyl)thio]-2H-pyran-2-yl)pentanoic acid and 12c, IC50 = 51 nM, 5,6-dihydro-4-hydroxy-6-phenyl-6-(2-phenylethyl)thio]-2H-pyran-2-one]. Optimization of the 3-position fragment to fill S-1' and S-2' afforded potent HIV protease inhibitor 49 [IC50 = 10 nM, 3-[(2-tert-butyl-5-methylphenyl)sulfanyl]-5,6-dihydro-4-hydroxy-6-phenyl-6-(2-phenylethyl)-2H-pyran-2-one]. The resulting low molecular weight compounds (<475) have one or no chiral centers and are readily synthesized.
引用
收藏
页码:3781 / 3792
页数:12
相关论文
共 50 条
  • [31] Exploring QSARs for Inhibitory Activity of Non-peptide HIV-1 Protease Inhibitors by GA-PLS and GA-SVM
    Deeb, Omar
    Goodarzi, Mohammad
    CHEMICAL BIOLOGY & DRUG DESIGN, 2010, 75 (05) : 506 - 514
  • [32] Hinnuliquinone, a C2-symmetric dimeric non-peptide fungal metabolite inhibitor of HIV-1 protease
    Singh, SB
    Ondeyka, JG
    Tsipouras, N
    Ruby, C
    Sardana, V
    Schulman, M
    Sanchez, M
    Pelaez, F
    Stahlhut, MW
    Munshi, S
    Olsen, DB
    Lingham, RB
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 324 (01) : 108 - 113
  • [33] Tipranavir (PNU-140690): A potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class
    Turner, SR
    Strohbach, JW
    Tommasi, RA
    Aristoff, PA
    Johnson, PD
    Skulnick, HI
    Dolak, LA
    Seest, EP
    Tomich, PK
    Bohanan, MJ
    Horng, MM
    Lynn, JC
    Chong, KT
    Hinshaw, RR
    Watenpaugh, KD
    Janakiraman, MN
    Thaisrivongs, S
    JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (18) : 3467 - 3476
  • [34] 6-hydroxy-1,3-dioxin-4-ones as non-peptidic HIV protease inhibitors
    Lee, YS
    Lee, YS
    Lee, JY
    Kim, SN
    Lee, CK
    Park, H
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2000, 10 (23) : 2625 - 2627
  • [35] STRUCTURE-BASED DESIGN OF HIV PROTEASE INHIBITORS - 4-HYDROXYCOUMARINS AND 4-HYDROXY-2-PYRONES AS NONPEPTIDIC INHIBITORS
    THAISRIVONGS, S
    TOMICH, PK
    WATENPAUGH, KD
    CHONG, KT
    HOWE, WJ
    YANG, CP
    STROHBACH, JW
    TURNER, SR
    MCGRATH, JP
    BOHANON, MJ
    LYNN, JC
    MULICHAK, AM
    SPINELLI, PA
    HINSHAW, RR
    PAGANO, PJ
    MOON, JB
    RUWART, MJ
    WILKINSON, KF
    RUSH, BD
    ZIPP, GL
    DALGA, RJ
    SCHWENDE, FJ
    HOWARD, GM
    PADBURY, GE
    TOTH, LN
    ZHAO, ZY
    KOEPLINGER, KA
    KAKUK, TJ
    COLE, SL
    ZAYA, RM
    PIPER, RC
    JEFFREY, P
    JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (20) : 3200 - 3204
  • [36] Substituted 4-hydroxy-6-phenyl-5,6-dihydropyridin-2-ones as potent inhibitors of human lactate dehydrogenase A
    Labadie, Sharada S.
    Dragovich, Peter S.
    Corson, Laura B.
    Ding, Charles
    Eigenbrot, Charles
    Evangelista, Marie
    Fauber, Benjamin
    Gao, Zhenting
    Hong, Rebecca
    Hitz, Anna
    Ho, Quynh
    Hunsaker, Thomas
    Kwong, Mandy
    Lai, Tommy
    Liu, Yichin
    Sampath, Deepak
    Ma, Shuguang
    Malek, Shiva
    O'Brien, Thomas
    Purkey, Hans E.
    Robarge, Kirk
    Salphati, Laurent
    Sideris, Steven
    Ultsch, Mark
    VanderPorten, Erica
    Wei, BinQing
    Yen, Ivana
    Zhang, Huihui
    Zhang, Xuying
    Zhou, Aihe
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 248
  • [37] QSAR analysis of 5,6-dihydro-4-hydroxy-2-pyrone analogues: HIV-1 protease inhibitor
    Jaiswal, Meenakshi
    Mishra, Richa
    Mishra, Brijeshkunvar
    Narayana Moorthy, N. S. Hari
    ASIAN JOURNAL OF CHEMISTRY, 2007, 19 (05) : 4110 - 4112
  • [38] 4-Hydroxy-5,6-dihydro-2H-pyran-2-ones.: 3.: Bicyclic and heteroaromatic ring systems as 3-position scaffolds to bind to S1′ and S2′ of the HIV-1 protease enzyme.
    Ellsworth, EL
    Domagala, J
    Prasad, JVNV
    Hagen, S
    Ferguson, D
    Holler, T
    Hupe, D
    Graham, N
    Nouhan, C
    Tummino, PJ
    Zeikus, G
    Lunney, EA
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1999, 9 (14) : 2019 - 2024
  • [39] Design, synthesis and structure activity relationship of tetrahydro-2-pyrimidinones as potent non-peptides HIV protease inhibitors
    DeLucca, I
    DeLucca, GV
    Lam, PYS
    Chang, CH
    Meek, J
    Rayner, M
    EricksonViitanen, S
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1996, 212 : 75 - ORGN